120 related articles for article (PubMed ID: 26853161)
1. Reply.
Bellaguarda E; Sakuraba A
Clin Gastroenterol Hepatol; 2016 May; 14(5):776-7. PubMed ID: 26853161
[No Abstract] [Full Text] [Related]
2. Natalizumab for Crohn's Disease: Down but Not Out.
Scott FI; Osterman MT
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1926-8. PubMed ID: 26196443
[No Abstract] [Full Text] [Related]
3. Failure to Account for Immortal Person Time Likely Accounts for the Apparent Reduction in Surgery Among Natalizumab Users.
Targownik LE
Clin Gastroenterol Hepatol; 2016 May; 14(5):776. PubMed ID: 26614877
[No Abstract] [Full Text] [Related]
4. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
5. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
Ropper AH
N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
[No Abstract] [Full Text] [Related]
6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab-associated progressive multifocal leukoencephalopathy.
Mancini N; Clementi M; Burioni R
N Engl J Med; 2012 Aug; 367(9):871-2; author reply 872. PubMed ID: 22931329
[No Abstract] [Full Text] [Related]
8. Natalizumab-associated progressive multifocal leukoencephalopathy.
Cervera C
N Engl J Med; 2012 Aug; 367(9):871; author reply 872. PubMed ID: 22931328
[No Abstract] [Full Text] [Related]
9. Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.
Zahednasab H
Neurology; 2012 Nov; 79(19):2010; author reply 2010-1. PubMed ID: 23128444
[No Abstract] [Full Text] [Related]
10. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
Warnke C; Adams O; Hartung HP; Gold R; Hemmer B; Hohlfeld R; Stangel M; Zipp F; Wiendl H; Kieseier BC
Nervenarzt; 2011 Oct; 82(10):1314-9. PubMed ID: 21656322
[No Abstract] [Full Text] [Related]
11. Considerations for characterizing the risk of PML in natalizumab-treated patients.
Koendgen H; Ho PR; Chang I
Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
[No Abstract] [Full Text] [Related]
12. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
13. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
14. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No.
Labauge P
Rev Neurol (Paris); 2017 Dec; 173(10):614-615. PubMed ID: 29102328
[No Abstract] [Full Text] [Related]
15. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
16. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? YES.
Wiertlewski S
Rev Neurol (Paris); 2017 Dec; 173(10):610-613. PubMed ID: 28760447
[No Abstract] [Full Text] [Related]
17. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
19. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
20. Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Rossi F; Prosperini L; De Rossi N; Capra R; Rivanera D; Li X; Cinque P; Passeri L; Pozzilli C; Viscidi R
Viral Immunol; 2017 Oct; 30(8):622-626. PubMed ID: 28836899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
